Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Samuel M. Rubinstein et al.|The Lancet|2020Cited by 1.8k
PD-L1 as a biomarker of response to immune-checkpoint inhibitorsDeborah B. Doroshow, Fred R. Hirsch, Sheena Bhalla et al.|Nature Reviews Clinical Oncology|2021Cited by 1.5k
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumPetros Grivas, Shuchi Gulati, Ali Raza Khaki et al.|Annals of Oncology|2021Cited by 326
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyDonna R. Rivera, Jeremy L. Warner, Solange Peters et al.|Cancer Discovery|2020Cited by 138
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes StudyAndrew Schmidt, Deborah B. Doroshow, Ziad Bakouny et al.|Cancer Cell|2020Cited by 72